Skip to main content
Article
AIM1 and LINE-1 Epigenetic Aberrations in Tumor and Serum Relate to Melanoma Progression and Disease Outcome
Journal of Investigative Dermatology (2012)
  • Sojun Hoshimoto, Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
  • Christine T. Kuo, Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
  • Kelly K. Chong, Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
  • Teh-Ling Takeshima, Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
  • Yoshiki Takei, Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
  • Michelle W. Li, Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
  • Sharon K. Huang, Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
  • Myung-Shin Sim, Department of Biostatistics, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
  • Donald L. Morton, Division of Surgical Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
  • Dave S.B. Hoon
Publication Date
June 1, 2012
DOI
10.1038/jid.2012.36
Citation Information
Sojun Hoshimoto, Christine T. Kuo, Kelly K. Chong, Teh-Ling Takeshima, et al.. "AIM1 and LINE-1 Epigenetic Aberrations in Tumor and Serum Relate to Melanoma Progression and Disease Outcome" Journal of Investigative Dermatology Vol. 132 Iss. 6 (2012) p. 1689 - 1697
Available at: http://works.bepress.com/dave-hoon/133/